A Randomized Controlled Trial on the Effect of Luseogliflozin on Bone Microarchitecture Evaluated Using HR-pQCT in Elderly Type 2 Diabetes

Riyoko Shigeno,Ichiro Horie,Ai Haraguchi,Ryuji Niimi,Ko Chiba,Shigeki Tashiro,Yurika Kawazoe,Shuntaro Sato,Makoto Osaki,Atsushi Kawakami,Norio Abiru
DOI: https://doi.org/10.1007/s13300-024-01634-2
2024-08-19
Diabetes Therapy
Abstract:Bone fragility is a critical issue in the treatment of elderly people with type 2 diabetes (T2D). In the Canagliflozin Cardiovascular Assessment Study, the subjects with T2D who were treated with canagliflozin showed a significant increase in fracture events compared to a placebo group as early as 12 weeks post-initiation. In addition, it has been unclear whether sodium-glucose co-transporter 2 (SGLT2) inhibitors promote bone fragility. We used high-resolution peripheral quantitative computed tomography (HR-pQCT) to prospectively evaluate the short-term effect of the SGLT2 inhibitor luseogliflozin on bone strength and microarchitecture in elderly people with T2D.
endocrinology & metabolism
What problem does this paper attempt to address?